VanEck Junior Gold Miners vs Koninklijke Philips NV — how do they compare? VanEck Junior Gold Miners trades at $114.43 (market cap $8.22B), while Koninklijke Philips NV trades at $24.22 (market cap $23.52B). The key difference: Koninklijke Philips NV is far larger — about 2.9× VanEck Junior Gold Miners's market cap, and Koninklijke Philips NV pays a 4.17% dividend while VanEck Junior Gold Miners pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Junior Gold Miners for 41 Days and Koninklijke Philips NV for 84 Days on average.
| GDXJ | PHG | |
|---|---|---|
Market Cap | $8.22B | $23.52B |
Volume | 3,212,198 | 1,635,069 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $32.91 |
52-Week Low | $87.56 | $23.81 |
Typical Hold Time | 41 Days | 84 Days |
Enterprise Value | — | $29.87B |
Dividend Yield | — | 4.17% |
Signals from Pluang's Aura AI — not financial advice
GDXJ, the VanEck Junior Gold Miners ETF, trades at $114.39, up 4.81% in the last 24 hours. The technical outlook is bearish, with moving averages and key indicators like ADX signaling selling pressure. Recent news highlights multiple junior gold mining companies being added to the ETF's underlying index, potentially increasing its diversification and appeal. However, key financial ratios such as P/E and P/S are unavailable for direct analysis of the ETF's valuation.
The outlook for GDXJ is mixed, balancing recent index additions against a bearish technical backdrop. Investment opportunities lie in exposure to junior gold miners amid high gold prices, but risks include sector volatility and the ETF's current negative momentum. Investors should weigh the potential for broader market recognition against prevailing selling pressure.
PHG trades at $24.225, up 0.56% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895 million in 2025 after previous losses, supported by strong operational cash flow of $1.17 billion. Recent news highlights Philips' innovation in healthcare technology including new product launches and strategic partnerships.
While valuation appears reasonable with P/E of 18.94 and EV/EBITDA of 8.86, the stock faces headwinds from bearish technical indicators and mixed analyst sentiment. Investment opportunity lies in continued earnings momentum and healthcare technology leadership, balanced against competitive pressures and execution risks in a challenging market environment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →